WO2008050101A2 - Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk - Google Patents
Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk Download PDFInfo
- Publication number
- WO2008050101A2 WO2008050101A2 PCT/GB2007/004018 GB2007004018W WO2008050101A2 WO 2008050101 A2 WO2008050101 A2 WO 2008050101A2 GB 2007004018 W GB2007004018 W GB 2007004018W WO 2008050101 A2 WO2008050101 A2 WO 2008050101A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- oxy
- methyl
- ring
- oxo
- Prior art date
Links
- 0 C*N(CCC1Oc2cc(C(N[*-])=O)cc(OCC3CCCCCCCCCC3)c2)C1=O Chemical compound C*N(CCC1Oc2cc(C(N[*-])=O)cc(OCC3CCCCCCCCCC3)c2)C1=O 0.000 description 6
- HPXOJPQAFOMIMH-UHFFFAOYSA-N CC(C)(CC1N=C(C)SC11)CN(C)C1=O Chemical compound CC(C)(CC1N=C(C)SC11)CN(C)C1=O HPXOJPQAFOMIMH-UHFFFAOYSA-N 0.000 description 1
- PSQUABYMZNNQCO-UHFFFAOYSA-N CC(N1C)Oc2cc(C)ncc2C1=O Chemical compound CC(N1C)Oc2cc(C)ncc2C1=O PSQUABYMZNNQCO-UHFFFAOYSA-N 0.000 description 1
- MWSPPXHFPFGTGL-UHFFFAOYSA-N CCOC(C(CCOS(C)(=O)=O)Oc1cc(C(NC2CCCCCCCCCC2)=O)cc(OC2CCCCCCCCCC2)c1)=O Chemical compound CCOC(C(CCOS(C)(=O)=O)Oc1cc(C(NC2CCCCCCCCCC2)=O)cc(OC2CCCCCCCCCC2)c1)=O MWSPPXHFPFGTGL-UHFFFAOYSA-N 0.000 description 1
- DIZMEAFMSTUYSG-KRWDZBQOSA-N CN(CC[C@@H]1Oc2cc(C(O)=O)cc(OCC3=CC=CCC3)c2)C1=O Chemical compound CN(CC[C@@H]1Oc2cc(C(O)=O)cc(OCC3=CC=CCC3)c2)C1=O DIZMEAFMSTUYSG-KRWDZBQOSA-N 0.000 description 1
- LMNSUDJGZAQNFZ-IBGZPJMESA-N CN(CC[C@@H]1Oc2cc(C(OC)=O)cc(Oc3ccc(C(N4CCC4)=O)nc3)c2)C1=O Chemical compound CN(CC[C@@H]1Oc2cc(C(OC)=O)cc(Oc3ccc(C(N4CCC4)=O)nc3)c2)C1=O LMNSUDJGZAQNFZ-IBGZPJMESA-N 0.000 description 1
- MCCHDLNYXQLUOF-SANMLTNESA-N CN(CC[C@@]1(C2)[O]2c2cc(C(Nc3cnccn3)=O)cc(Oc3ccc(C(N4CCC4)=O)[n]c3)c2)C1=O Chemical compound CN(CC[C@@]1(C2)[O]2c2cc(C(Nc3cnccn3)=O)cc(Oc3ccc(C(N4CCC4)=O)[n]c3)c2)C1=O MCCHDLNYXQLUOF-SANMLTNESA-N 0.000 description 1
- CTEBEGRPFDCLGB-MRXNPFEDSA-N CN(CC[C@H]1Oc2cc(C(O)=O)cc(Oc(nc3)cnc3C(N3CCC3)=O)c2)C1=O Chemical compound CN(CC[C@H]1Oc2cc(C(O)=O)cc(Oc(nc3)cnc3C(N3CCC3)=O)c2)C1=O CTEBEGRPFDCLGB-MRXNPFEDSA-N 0.000 description 1
- VIRCJHXCIJZYFM-GOSISDBHSA-N CN(CC[C@H]1Oc2cc(OCc3ccccc3)cc(C(OC)=O)c2)C1=O Chemical compound CN(CC[C@H]1Oc2cc(OCc3ccccc3)cc(C(OC)=O)c2)C1=O VIRCJHXCIJZYFM-GOSISDBHSA-N 0.000 description 1
- UOBNYWWAFHZZEV-LNOPCHKWSA-N C[C@H](C[C@H](C)N1CC(C2)C2CC1)N(C1)C2C1CCCC2 Chemical compound C[C@H](C[C@H](C)N1CC(C2)C2CC1)N(C1)C2C1CCCC2 UOBNYWWAFHZZEV-LNOPCHKWSA-N 0.000 description 1
- YBMJQKYIFVIDSQ-UHFFFAOYSA-N C[IH]C1=NC(CCCNC2=O)C2S1 Chemical compound C[IH]C1=NC(CCCNC2=O)C2S1 YBMJQKYIFVIDSQ-UHFFFAOYSA-N 0.000 description 1
- UYLQVQJCPPHRPY-UHFFFAOYSA-N Cc(cc1)nc(OCCN2C)c1C2=O Chemical compound Cc(cc1)nc(OCCN2C)c1C2=O UYLQVQJCPPHRPY-UHFFFAOYSA-N 0.000 description 1
- MXCCJTBJMZMAFR-UHFFFAOYSA-N Cc(nc1)cc(OCCN2C)c1C2=O Chemical compound Cc(nc1)cc(OCCN2C)c1C2=O MXCCJTBJMZMAFR-UHFFFAOYSA-N 0.000 description 1
- XCLYOYZJUQUPED-UHFFFAOYSA-N Cc1cc(OCCN(C)C2=O)c2nc1 Chemical compound Cc1cc(OCCN(C)C2=O)c2nc1 XCLYOYZJUQUPED-UHFFFAOYSA-N 0.000 description 1
- DXYYSGDWQCSKKO-UHFFFAOYSA-N Cc1nc(cccc2)c2[s]1 Chemical compound Cc1nc(cccc2)c2[s]1 DXYYSGDWQCSKKO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Catching Or Destruction (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007310608A AU2007310608A1 (en) | 2006-10-23 | 2007-10-22 | Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through GLK |
BRPI0718504-9A BRPI0718504A2 (pt) | 2006-10-23 | 2007-10-22 | Composto ou um sal do mesmo, composição farmacêutica, uso de um composto ou um sal do mesmo farmaceuticamente aceitável, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto |
MX2009004362A MX2009004362A (es) | 2006-10-23 | 2007-10-22 | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. |
CA002667435A CA2667435A1 (en) | 2006-10-23 | 2007-10-22 | Chemical compounds |
JP2009533935A JP2010507640A (ja) | 2006-10-23 | 2007-10-22 | 化合物 |
EP07824267A EP2086964A2 (en) | 2006-10-23 | 2007-10-22 | Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk |
IL198142A IL198142A0 (en) | 2006-10-23 | 2009-04-16 | Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk |
NO20091599A NO20091599L (no) | 2006-10-23 | 2009-04-22 | Kjemiske forbindelser |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86249306P | 2006-10-23 | 2006-10-23 | |
US60/862,493 | 2006-10-23 | ||
US89199307P | 2007-02-28 | 2007-02-28 | |
US60/891,993 | 2007-02-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008050101A2 true WO2008050101A2 (en) | 2008-05-02 |
WO2008050101A3 WO2008050101A3 (en) | 2008-07-17 |
Family
ID=39324963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/004018 WO2008050101A2 (en) | 2006-10-23 | 2007-10-22 | Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk |
Country Status (18)
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2010150280A1 (en) * | 2009-06-22 | 2010-12-29 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (gk) activators |
WO2011013141A2 (en) | 2009-07-31 | 2011-02-03 | Cadila Healthcare Limited | Substituted benzamide derivatives as glucokinase (gk) activators |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2011161030A1 (de) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2016168633A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
US11690841B2 (en) | 2017-09-14 | 2023-07-04 | Queen Mary University Of London | Glycolysis-activating agents for treatment or prevention of disease |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070007103A (ko) * | 2004-02-18 | 2007-01-12 | 아스트라제네카 아베 | 벤즈아미드 유도체 및 이의 글루코키나아제 활성화제로서의용도 |
TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
NZ575514A (en) * | 2005-07-09 | 2009-11-27 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
SA07280576B1 (ar) * | 2006-10-26 | 2011-06-22 | استرازينيكا ايه بي | مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز |
EP2324028A2 (en) | 2008-08-04 | 2011-05-25 | AstraZeneca AB | Therapeutic agents 414 |
GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
AR076220A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivados de pirazol [4,5 - e] pirimidina |
AR076221A1 (es) * | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1600442A1 (en) * | 2003-02-26 | 2005-11-30 | Banyu Pharmaceutical Co., Ltd. | Heteroarylcarbamoylbenzene derivative |
WO2005121110A1 (en) * | 2004-06-05 | 2005-12-22 | Astrazeneca Ab | Hetroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
WO2006125958A1 (en) * | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators |
WO2007007041A1 (en) * | 2005-07-09 | 2007-01-18 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
WO2007017649A1 (en) * | 2005-08-09 | 2007-02-15 | Astrazeneca Ab | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes |
WO2007053657A1 (en) * | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted pyrrolones as allosteric modulators of glucokinase |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2750393A (en) * | 1954-12-01 | 1956-06-12 | Sterling Drug Inc | Iodinated 5-henzamidotetrazoles and preparation thereof |
US2967194A (en) * | 1958-05-15 | 1961-01-03 | Pennsalt Chemicals Corp | 4-trifluoromethylsalicylamides |
FR1526074A (fr) | 1967-03-22 | 1968-05-24 | Rech S Ind S O R I Soc D | Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation |
GB1352415A (en) | 1970-05-03 | 1974-05-08 | Boots Co Ltd | Esters of substituted nicotine acids |
FR2088019A1 (en) | 1970-05-08 | 1972-01-07 | Rabot Ets David | Esters of 2 and 6-substituted nicotinic acids - with vasomotor active |
CS173097B1 (US07902200-20110308-C00088.png) | 1972-12-01 | 1977-02-28 | ||
GB1400540A (en) * | 1972-12-06 | 1975-07-16 | Smith Kline French Lab | Salicylamides and compositions thereof |
US4009174A (en) * | 1972-12-08 | 1977-02-22 | The Boots Company Limited | Esters of substituted nicotinic acids |
GB1437800A (en) * | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
JPS5734314B2 (US07902200-20110308-C00088.png) | 1973-12-22 | 1982-07-22 | ||
GB1561350A (en) | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
FR2344284A1 (fr) * | 1976-03-17 | 1977-10-14 | Cerm Cent Europ Rech Mauvernay | Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs |
GB1588242A (en) | 1977-10-28 | 1981-04-23 | May & Baker Ltd | N-(tetrazol-5-yl)-salicylamide derivatives |
US4474792A (en) * | 1979-06-18 | 1984-10-02 | Riker Laboratories, Inc. | N-Tetrazolyl benzamides and anti-allergic use thereof |
JPS5721320A (en) | 1980-07-11 | 1982-02-04 | Chugai Pharmaceut Co Ltd | Blood sugar level depressing agent |
JPS5775962A (en) | 1980-10-29 | 1982-05-12 | Shionogi & Co Ltd | 2-alkoxybenzamide derivative |
FR2493848B2 (fr) * | 1980-11-07 | 1986-05-16 | Delalande Sa | Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique |
JPS5869812A (ja) | 1981-10-22 | 1983-04-26 | Chugai Pharmaceut Co Ltd | 血糖降下剤 |
JPS59139357A (ja) * | 1983-01-28 | 1984-08-10 | Torii Yakuhin Kk | アミジン誘導体 |
JPS61205937A (ja) | 1985-03-09 | 1986-09-12 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀カラ−写真感光材料 |
JPS62142168A (ja) | 1985-10-16 | 1987-06-25 | Mitsubishi Chem Ind Ltd | チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤 |
JPS62158252A (ja) | 1985-12-28 | 1987-07-14 | Kirin Brewery Co Ltd | 4−アミノピリジンベンズアミド誘導体 |
CA1327358C (en) * | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
JP2852659B2 (ja) | 1988-03-03 | 1999-02-03 | 富山化学工業株式会社 | ピペラジン誘導体およびその塩 |
DE3822449A1 (de) | 1988-07-02 | 1990-01-04 | Henkel Kgaa | Oxidationshaarfaerbemittel mit neuen kupplern |
JPH04300874A (ja) | 1991-03-29 | 1992-10-23 | Tsumura & Co | 新規2,4−ジアミノ−1,3,5−トリアジン誘導体 |
JPH04300832A (ja) | 1991-03-29 | 1992-10-23 | Tsumura & Co | 2,4−ジアミノ−1,3,5−トリアジン誘導体を有 効成分とするロイコトリエン拮抗剤 |
US5466715A (en) * | 1991-12-31 | 1995-11-14 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5258407A (en) * | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5273986A (en) * | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
JPH0627025A (ja) | 1992-07-06 | 1994-02-04 | Toto Ltd | 分子認識機能膜及びこれを用いたセンサー |
EP0619116A3 (en) | 1993-04-05 | 1994-11-23 | Hoechst Japan | Use of synthetic retinoids for osteopathy. |
GB9307527D0 (en) | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
US5661153A (en) * | 1994-07-19 | 1997-08-26 | Japan Energy Corporation | 1-arylpyrimidine derivatives and pharmaceutical use thereof |
US5792109A (en) | 1994-09-01 | 1998-08-11 | Leland L. Ladd | Irrigation pump and system |
JPH08143565A (ja) | 1994-11-16 | 1996-06-04 | Fujisawa Pharmaceut Co Ltd | ベンズアミド化合物 |
US5510478A (en) * | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
US5672750A (en) * | 1994-12-16 | 1997-09-30 | Eastman Chemical Company | Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride |
US5849735A (en) * | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
JPH08301760A (ja) | 1995-05-10 | 1996-11-19 | Shiseido Co Ltd | 皮膚外用剤 |
JP3168915B2 (ja) | 1995-05-25 | 2001-05-21 | 田辺製薬株式会社 | 医薬組成物 |
US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
JP3735741B2 (ja) | 1995-11-24 | 2006-01-18 | 株式会社大塚製薬工場 | 縮環ピリミジン誘導体 |
JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
FR2757852B1 (fr) * | 1996-12-31 | 1999-02-19 | Cird Galderma | Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations |
JPH10212271A (ja) | 1997-01-31 | 1998-08-11 | Zeria Pharmaceut Co Ltd | N−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体 |
JPH1129480A (ja) | 1997-05-12 | 1999-02-02 | Otsuka Pharmaceut Factory Inc | 縮環ピリミジン誘導体を含有する医薬組成物 |
CA2295239A1 (en) * | 1997-06-27 | 1999-01-07 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonamide compounds and medicinal use thereof |
WO1999000359A1 (fr) * | 1997-06-27 | 1999-01-07 | Fujisawa Pharmaceutical Co., Ltd. | Derives de noyau aromatique |
US6613942B1 (en) * | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6114483A (en) | 1997-08-27 | 2000-09-05 | E. I. Du Pont De Nemours And Company | Polymerization of olefins |
JP4398585B2 (ja) | 1997-11-12 | 2010-01-13 | 有限会社ケムフィズ | レチノイドレセプター作用剤 |
GB9725298D0 (en) | 1997-11-28 | 1998-01-28 | Zeneca Ltd | Insecticidal thiazole derivatives |
US6200995B1 (en) * | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
DE19816780A1 (de) * | 1998-04-16 | 1999-10-21 | Bayer Ag | Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide |
GB9811969D0 (en) * | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
US6197798B1 (en) * | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
JP4191825B2 (ja) | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | 5−アミノイソキサゾール誘導体 |
RU2242469C2 (ru) * | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Активаторы глюкокиназы |
US6610846B1 (en) * | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
AU1917201A (en) * | 1999-11-18 | 2001-05-30 | Centaur Pharmaceuticals, Inc. | Amide therapeutics and methods for treating inflammatory bowel disease |
WO2001064642A2 (en) * | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
EP1132381A1 (en) | 2000-03-08 | 2001-09-12 | Cermol S.A. | Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them |
US6534651B2 (en) * | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
AU7049401A (en) * | 2000-05-03 | 2001-11-12 | Hoffmann La Roche | Alkynyl phenyl heteroaromatic glucokinase activators |
RU2276137C2 (ru) * | 2000-11-22 | 2006-05-10 | Астеллас Фарма Инк. | Замещенные производные бензола или их соли, фармацевтическая композиция на их основе |
PT1341774E (pt) * | 2000-12-06 | 2006-05-31 | Hoffmann La Roche | Activadores heteroaromaticos, fundidos de glicocinase |
CA2432713C (en) * | 2000-12-22 | 2009-10-27 | Ishihara Sangyo Kaisha, Ltd. | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
US20040077697A1 (en) | 2001-02-02 | 2004-04-22 | Hiroyuki Koshio | 2-Acylaminothiazole derivative or its salt |
SE0102299D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
MXPA04001253A (es) * | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
EP1336607A1 (en) | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
JP4419571B2 (ja) | 2002-03-26 | 2010-02-24 | 萬有製薬株式会社 | 新規アミノベンズアミド誘導体 |
JPWO2004007472A1 (ja) * | 2002-07-10 | 2005-11-17 | 小野薬品工業株式会社 | Ccr4アンタゴニストおよびその医薬用途 |
GB0226931D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0325402D0 (en) * | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
US7767670B2 (en) * | 2003-11-13 | 2010-08-03 | Ambit Biosciences Corporation | Substituted 3-carboxamido isoxazoles as kinase modulators |
KR20060105872A (ko) | 2003-12-29 | 2006-10-11 | 반유 세이야꾸 가부시끼가이샤 | 신규한 2-헤테로아릴 치환된 벤즈이미다졸 유도체 |
JP5033119B2 (ja) | 2005-04-25 | 2012-09-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナーゼ阻害剤としての新規アザ複素環化合物 |
-
2007
- 2007-10-19 TW TW096139393A patent/TW200825063A/zh unknown
- 2007-10-22 MX MX2009004362A patent/MX2009004362A/es not_active Application Discontinuation
- 2007-10-22 AU AU2007310608A patent/AU2007310608A1/en not_active Abandoned
- 2007-10-22 US US11/876,370 patent/US7902200B2/en not_active Expired - Fee Related
- 2007-10-22 BR BRPI0718504-9A patent/BRPI0718504A2/pt not_active Application Discontinuation
- 2007-10-22 CL CL200703033A patent/CL2007003033A1/es unknown
- 2007-10-22 AR ARP070104658A patent/AR063499A1/es unknown
- 2007-10-22 WO PCT/GB2007/004018 patent/WO2008050101A2/en active Application Filing
- 2007-10-22 CA CA002667435A patent/CA2667435A1/en not_active Abandoned
- 2007-10-22 RU RU2009114982/04A patent/RU2009114982A/ru not_active Application Discontinuation
- 2007-10-22 JP JP2009533935A patent/JP2010507640A/ja not_active Withdrawn
- 2007-10-22 PE PE2007001425A patent/PE20081467A1/es not_active Application Discontinuation
- 2007-10-22 EP EP07824267A patent/EP2086964A2/en not_active Withdrawn
- 2007-10-22 KR KR1020097010059A patent/KR20090068289A/ko not_active Application Discontinuation
- 2007-10-29 UY UY30660A patent/UY30660A1/es unknown
-
2009
- 2009-04-16 IL IL198142A patent/IL198142A0/en unknown
- 2009-04-20 CO CO09039732A patent/CO6160318A2/es unknown
- 2009-04-22 NO NO20091599A patent/NO20091599L/no not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1600442A1 (en) * | 2003-02-26 | 2005-11-30 | Banyu Pharmaceutical Co., Ltd. | Heteroarylcarbamoylbenzene derivative |
WO2005121110A1 (en) * | 2004-06-05 | 2005-12-22 | Astrazeneca Ab | Hetroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
WO2006125958A1 (en) * | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators |
WO2007007041A1 (en) * | 2005-07-09 | 2007-01-18 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
WO2007017649A1 (en) * | 2005-08-09 | 2007-02-15 | Astrazeneca Ab | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes |
WO2007053657A1 (en) * | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted pyrrolones as allosteric modulators of glucokinase |
Non-Patent Citations (1)
Title |
---|
SHORVON S: "Pyrrolidone derivatives" LANCET THE, LANCET LIMITED. LONDON, GB, vol. 358, no. 9296, 1 December 2001 (2001-12-01), pages 1885-1892, XP004806490 ISSN: 0140-6736 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2010150280A1 (en) * | 2009-06-22 | 2010-12-29 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (gk) activators |
US8450494B2 (en) | 2009-06-22 | 2013-05-28 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (GK) activators |
CN102482267A (zh) * | 2009-07-31 | 2012-05-30 | 卡迪拉保健有限公司 | 作为葡萄糖激酶(gk)活化剂的取代苯甲酰胺衍生物 |
WO2011013141A2 (en) | 2009-07-31 | 2011-02-03 | Cadila Healthcare Limited | Substituted benzamide derivatives as glucokinase (gk) activators |
WO2011013141A3 (en) * | 2009-07-31 | 2011-03-24 | Cadila Healthcare Limited | Substituted benzamide derivatives as glucokinase (gk) activators |
CN102482267B (zh) * | 2009-07-31 | 2014-12-03 | 卡迪拉保健有限公司 | 作为葡萄糖激酶(gk)活化剂的取代苯甲酰胺衍生物 |
AU2010277171B2 (en) * | 2009-07-31 | 2013-02-07 | Cadila Healthcare Limited | Substituted benzamide derivatives as glucokinase (GK) activators |
JP2013500961A (ja) * | 2009-07-31 | 2013-01-10 | カディラ ヘルスケア リミテッド | グルコキナーゼ(gk)アクチベーターとしての置換ベンズアミド誘導体 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2011161030A1 (de) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2016168633A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
US11690841B2 (en) | 2017-09-14 | 2023-07-04 | Queen Mary University Of London | Glycolysis-activating agents for treatment or prevention of disease |
Also Published As
Publication number | Publication date |
---|---|
CL2007003033A1 (es) | 2008-05-16 |
CA2667435A1 (en) | 2008-05-02 |
KR20090068289A (ko) | 2009-06-25 |
CO6160318A2 (es) | 2010-05-20 |
UY30660A1 (es) | 2008-05-31 |
AU2007310608A1 (en) | 2008-05-02 |
IL198142A0 (en) | 2009-12-24 |
PE20081467A1 (es) | 2008-12-07 |
TW200825063A (en) | 2008-06-16 |
US20080171734A1 (en) | 2008-07-17 |
NO20091599L (no) | 2009-07-21 |
EP2086964A2 (en) | 2009-08-12 |
US7902200B2 (en) | 2011-03-08 |
RU2009114982A (ru) | 2010-11-27 |
BRPI0718504A2 (pt) | 2013-12-03 |
AR063499A1 (es) | 2009-01-28 |
WO2008050101A3 (en) | 2008-07-17 |
JP2010507640A (ja) | 2010-03-11 |
MX2009004362A (es) | 2009-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7902200B2 (en) | Chemical compounds | |
AU2006268406C1 (en) | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | |
AU2007310624B2 (en) | Benzoyl amino heterocyclyl compounds as glucokinase (GLK) activators | |
US20080234273A1 (en) | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | |
US20080280874A1 (en) | Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity | |
WO2007007040A1 (en) | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes | |
US20090105214A1 (en) | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | |
US20070287693A1 (en) | Benzamide Derivatives That Act Upon The Glucokinase Enzyme | |
EP1718625A1 (en) | Compounds | |
EP1915367A1 (en) | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes | |
EP1756076A1 (en) | Hetroaryl benzamide derivatives for use as glk activators in the treatment of diabetes | |
WO2007031739A1 (en) | Heterobicyclic compounds as glucokinase activators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780048084.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007310608 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2373/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 198142 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09039732 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009040544 Country of ref document: EG Ref document number: 2667435 Country of ref document: CA Ref document number: 12009500762 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 576413 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2009533935 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/004362 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007824267 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007310608 Country of ref document: AU Date of ref document: 20071022 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097010059 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2009114982 Country of ref document: RU Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07824267 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: PI0718504 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090422 |